Related Experiment Video
Updated: Jul 4, 2026
The Utilization of Oropharyngeal Intratracheal PAMP Administration and Bronchoalveolar Lavage to Evaluate the Host Immune Response in Mice
Published on: April 2, 2014
The impact of bacterial lysate (OM-85) on clinical and immunological parameters in children with allergic rhinitis
Huajie Yan1, Jiayi Hong2, Chunyun Zeng3
1Department of Pediatrics, Shanghai Jiading Nanxiang Hospital, No. 495, Zhongren Road, Nanxiang Town, Jiading District, Shanghai, 201802, China. yan_yhuajie37@163.com.
Insights
Bacterial lysate (OM-85) improved quality of life and reduced allergic rhinitis episodes in children. This adjunctive therapy also enhanced immune function, increasing NK and Treg cells while decreasing CD8+ T cells.
Area of Science:
- Pediatric Allergy and Immunology
- Immunotherapy
- Respiratory Medicine
Background:
- Allergic rhinitis (AR) significantly impacts children's quality of life.
- Standard treatments for AR may not fully address underlying immune dysregulation.
Purpose of the Study:
- To assess the clinical effectiveness of bacterial lysate (OM-85) as an add-on therapy for pediatric allergic rhinitis.
- To investigate the immunomodulatory effects of OM-85 in children with AR.
Main Methods:
- A randomized controlled trial involving 40 children (5-14 years) with AR.
- Comparison of standard treatment (mometasone furoate nasal spray, cetirizine) versus standard treatment plus OM-85.
- Evaluation of changes in quality of life (RQLQ scores) and immune parameters (lymphocyte subsets, immunoglobulins).
Main Results:
- Both groups experienced reduced AR episode frequency.
- The OM-85 group showed significantly greater improvements in RQLQ scores across multiple domains.
- OM-85 treatment led to increased NK and Treg cells, elevated IgA and IgG, and decreased CD8+ T cells. No significant immune changes were noted in the control group.
Conclusions:
- Adjunctive OM-85 therapy is effective in improving clinical symptoms and quality of life for children with allergic rhinitis.
- OM-85 demonstrates immunomodulatory effects, enhancing immune function in pediatric AR patients.
Objective:
To evaluate the clinical efficacy and immunomodulatory effects of bacterial lysate (OM-85) in children with allergic rhinitis (AR).
Method:
A total of 40 children aged 5 to 14 years with AR were selected and divided into two groups: the control group (treated with mometasone furoate nasal spray and cetirizine) and the observation group (treated with the same regimen as the control group, plus OM-85). The changes in Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) scores, lymphocyte subsets, and serum immunoglobulin levels were compared before and after treatment between the two groups.
Results:
After treatment, both groups showed a significant reduction in the frequency of allergic rhinitis episodes (P < 0.05). The RQLQ scores indicated that the observation group showed more significant improvements in daily activities, rhinitis-related behaviors, nasal symptoms, emotional responses, and overall score (P < 0.05), while the control group showed improvements in only some of the indicators (P < 0.05). In the observation group, NK cell levels (6.28% [3.46; 8.55] vs. 7.80% [5.90; 13.87], P = 0.025), Treg cell levels (0.83 ± 0.50% vs. 1.20 ± 0.47%, P = 0.016), serum IgA (0.97 ± 0.34 vs. 1.49 ± 0.58 g/L, P = 0.001), and IgG levels (9.32 ± 2.85 vs. 11.11 ± 2.09 g/L, P = 0.019) were significantly increased, while CD8 + T cell levels decreased (28.84 ± 5.24% vs. 25.62 ± 5.85%, P = 0.037). No significant changes in immune parameters were observed in the control group (P > 0.05).
Conclusion:
OM-85 adjunctive therapy can enhance immune function, improve clinical symptoms, and enhance quality of life in children with allergic rhinitis.
